Targeted News Service

Sacituzumab Govitecan-hziy Led to Similar Progression-free Survival as Standard of Care for Certain Endocrine Therapy-refractory Advanced Breast Cancers
December 10, 2025

PHILADELPHIA, Pennsylvania, Dec. 10 [Category: Medical] -- The American Association for Cancer Research posted the following news release:

* * *

Sacituzumab Govitecan-hziy Led to Similar Progression-free Survival as Standard of Care for Certain Endocrine Therapy-refractory Advanced Breast Cancers

*

SAN ANTONIO - Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whethe . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form